Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 405

1.

MiR-106a targets Mcl-1 to suppress cisplatin resistance of ovarian cancer A2780 cells.

Rao YM, Shi HR, Ji M, Chen CH.

J Huazhong Univ Sci Technolog Med Sci. 2013 Aug;33(4):567-72. doi: 10.1007/s11596-013-1160-5. Epub 2013 Aug 1.

PMID:
23904379
2.

MiR-152 and miR-185 co-contribute to ovarian cancer cells cisplatin sensitivity by targeting DNMT1 directly: a novel epigenetic therapy independent of decitabine.

Xiang Y, Ma N, Wang D, Zhang Y, Zhou J, Wu G, Zhao R, Huang H, Wang X, Qiao Y, Li F, Han D, Wang L, Zhang G, Gao X.

Oncogene. 2014 Jan 16;33(3):378-86. doi: 10.1038/onc.2012.575. Epub 2013 Jan 14.

PMID:
23318422
3.

Downregulation of miR-130a contributes to cisplatin resistance in ovarian cancer cells by targeting X-linked inhibitor of apoptosis (XIAP) directly.

Zhang X, Huang L, Zhao Y, Tan W.

Acta Biochim Biophys Sin (Shanghai). 2013 Dec;45(12):995-1001. doi: 10.1093/abbs/gmt113. Epub 2013 Oct 20.

PMID:
24145606
4.

MiR-130a and MiR-374a Function as Novel Regulators of Cisplatin Resistance in Human Ovarian Cancer A2780 Cells.

Li N, Yang L, Wang H, Yi T, Jia X, Chen C, Xu P.

PLoS One. 2015 Jun 4;10(6):e0128886. doi: 10.1371/journal.pone.0128886. eCollection 2015.

5.

miR-125b confers resistance of ovarian cancer cells to cisplatin by targeting pro-apoptotic Bcl-2 antagonist killer 1.

Kong F, Sun C, Wang Z, Han L, Weng D, Lu Y, Chen G.

J Huazhong Univ Sci Technolog Med Sci. 2011 Aug;31(4):543-9. doi: 10.1007/s11596-011-0487-z. Epub 2011 Aug 7.

PMID:
21823019
6.

MicroRNA-133b targets glutathione S-transferase π expression to increase ovarian cancer cell sensitivity to chemotherapy drugs.

Chen S, Jiao JW, Sun KX, Zong ZH, Zhao Y.

Drug Des Devel Ther. 2015 Sep 16;9:5225-35. doi: 10.2147/DDDT.S87526. eCollection 2015.

7.

[Regulatory effects and associated mechanisms of miR-130a molecules on cisplatin resistance in ovarian cancer A2780 cell lines].

Li NW, Wang HJ, Yang LY, Jia XB, Chen C, Wang X.

Sichuan Da Xue Xue Bao Yi Xue Ban. 2013 Nov;44(6):865-70. Chinese.

PMID:
24490491
8.

MicroRNA-106a confers cisplatin resistance in non-small cell lung cancer A549 cells by targeting adenosine triphosphatase-binding cassette A1.

Ma Y, Li X, Cheng S, Wei W, Li Y.

Mol Med Rep. 2015 Jan;11(1):625-32. doi: 10.3892/mmr.2014.2688. Epub 2014 Oct 17.

PMID:
25339370
9.

[Expression of miR-130a in cisplatin resistant cell lines of ovarian cancer].

Yang LY, Wang HJ, Jia XB, Wang X, Luo J, Zhang XY.

Sichuan Da Xue Xue Bao Yi Xue Ban. 2012 Jan;43(1):60-4. Chinese.

PMID:
22455133
10.

Effect of lung resistance-related protein on the resistance to cisplatin in human ovarian cancer cell lines.

Wang W, Ke S, Chen G, Gao Q, Wu S, Wang S, Zhou J, Yang X, Lu Y, Ma D.

Oncol Rep. 2004 Dec;12(6):1365-70.

PMID:
15547764
11.

The passenger strand, miR-21-3p, plays a role in mediating cisplatin resistance in ovarian cancer cells.

Pink RC, Samuel P, Massa D, Caley DP, Brooks SA, Carter DR.

Gynecol Oncol. 2015 Apr;137(1):143-51. doi: 10.1016/j.ygyno.2014.12.042. Epub 2015 Jan 8.

PMID:
25579119
12.

MDR1 and MDR3 genes and drug resistance to cisplatin of ovarian cancer cells.

Ren L, Xiao L, Hu J.

J Huazhong Univ Sci Technolog Med Sci. 2007 Dec;27(6):721-4. doi: 10.1007/s11596-007-0627-7.

PMID:
18231753
13.

Interference with the expression of β-catenin reverses cisplatin resistance in A2780/DDP cells and inhibits the progression of ovarian cancer in mouse model.

Zhao H, Wei W, Sun Y, Gao J, Wang Q, Zheng J.

DNA Cell Biol. 2015 Jan;34(1):55-62. doi: 10.1089/dna.2014.2626.

PMID:
25211326
14.

miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells.

van Jaarsveld MT, Helleman J, Boersma AW, van Kuijk PF, van Ijcken WF, Despierre E, Vergote I, Mathijssen RH, Berns EM, Verweij J, Pothof J, Wiemer EA.

Oncogene. 2013 Sep 5;32(36):4284-93. doi: 10.1038/onc.2012.433. Epub 2012 Oct 8.

PMID:
23045278
15.

The inhibition of miR-21 promotes apoptosis and chemosensitivity in ovarian cancer.

Chan JK, Blansit K, Kiet T, Sherman A, Wong G, Earle C, Bourguignon LY.

Gynecol Oncol. 2014 Mar;132(3):739-44. doi: 10.1016/j.ygyno.2014.01.034. Epub 2014 Jan 25.

PMID:
24472409
16.

MicroRNA-449a reduces cell survival and enhances cisplatin-induced cytotoxicity via downregulation of NOTCH1 in ovarian cancer cells.

Zhou Y, Chen Q, Qin R, Zhang K, Li H.

Tumour Biol. 2014 Dec;35(12):12369-78. doi: 10.1007/s13277-014-2551-3. Epub 2014 Sep 2.

PMID:
25179844
17.

miR-21 confers cisplatin resistance in gastric cancer cells by regulating PTEN.

Yang SM, Huang C, Li XF, Yu MZ, He Y, Li J.

Toxicology. 2013 Apr 5;306:162-8. doi: 10.1016/j.tox.2013.02.014. Epub 2013 Mar 4.

PMID:
23466500
18.

miR-106a confers cisplatin resistance by regulating PTEN/Akt pathway in gastric cancer cells.

Fang Y, Shen H, Li H, Cao Y, Qin R, Long L, Zhu X, Xie C, Xu W.

Acta Biochim Biophys Sin (Shanghai). 2013 Nov;45(11):963-72. doi: 10.1093/abbs/gmt106. Epub 2013 Oct 9.

PMID:
24108762
19.

Oridonin effectively reverses cisplatin drug resistance in human ovarian cancer cells via induction of cell apoptosis and inhibition of matrix metalloproteinase expression.

Ma S, Tan W, Du B, Liu W, Li W, Che D, Zhang G.

Mol Med Rep. 2016 Apr;13(4):3342-8. doi: 10.3892/mmr.2016.4897. Epub 2016 Feb 16.

PMID:
26935490
20.

Regulation of HtrA2/Omi by X-linked inhibitor of apoptosis protein in chemoresistance in human ovarian cancer cells.

Yang X, Xing H, Gao Q, Chen G, Lu Y, Wang S, Ma D.

Gynecol Oncol. 2005 May;97(2):413-21.

PMID:
15863139

Supplemental Content

Support Center